anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The fat-soluble vitamin is extracted from fish oils, fish-liver oils, butter and other milk fats, &c., by converting the fatty material into an insoluble soap, either directly or through the intermediary of a soluble soap, and treating the insoluble soap with an organic solvent.  The access of air during the extraction process should be avoided.  According to the examples (1) a solution of the vitamin is obtained by saponifying cod-liver oil hot or cold with alcoholic calcium or barium hydroxide and filtering the product, or by saponifying the oil with calcium or barium hydroxide under ordinary or increased pressure and treating the product with alcohol or ether; (2) the raw material is saponified hot or cold with alcoholic caustic potash or soda, calcium or barium chloride then added, and the soaps removed by filtration.  In both cases, any calcium or barium hydroxide remaining in the product is precipitated by passing carbon dioxide, and the evaporated filtrate is then treated with ether, benzene or chloroform, which takes up the vitamin leaving behind the glycerin and mineral salts.  Any soap present is removed by conversion into the alkali soap and washing this out with water. Small quantities of fatty acid still remain and these are eliminated by treatment with potassium carbonate, followed if necessary by the addition of dilute silver nitrate solution.  A crude vitamin is obtained which is freed from cholesterol by dissolving it in 85-90 per cent methyl alcohol and allowing the cholesterol to crystallize out.  The properties of the product are described.  The vitamin may conveniently be dissolved in fatty matter or alcohol, or be absorbed by lactose, starch or the like.  The Specification makes reference to the results obtained when cod-liver oil and butter are subjected to hot or cold saponification with various agents and describes the extraction of the vitamin from cod-liver oil by adding oleic acid thereto, extracting with alcohol and freeing the extract from its oleic content.  Specification 227,122 is referred to.
Controlled Substance

Phendimetrazine tartrate tablets are defined by the Drug Enforcement Administration as a Schedule lll controlled substance.

  
Dependence

Phendimetrazine tartrate is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been extensively abused and the possibility of abuse of phendimetrazine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia.

  
Overdosage

Acute overdosage with phendimetrazine tartrate may manifest itself by the following signs and symptoms: unusual restlessness, confusion, belligerence, hallucinations and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Poisoning may result in convulsions, coma and death.

The management of overdosage is largely symptomatic. It includes sedation with a barbiturate. If hypertension is marked, the use of a nitrate or rapid-acting alpha receptor-blocking agent should be considered. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations for its use.
Participants receive the recommended phase 2 dose of Talquetamab and Iberdomide, and 20-40mg of Dexamethasone which may be continued at the discretion of the investigator. Treatment repeats every 35 days for cycle 1 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Participants also undergo bone marrow biopsy, imaging scans, tissue and blood sample collection throughout the study.
BACKGROUND: Immune thrombocytopenia (ITP) is defined as an isolated platelet count less than 100 × 109/L in the absence of other causes of thrombocytopenia. Sarcopenia is a body-wide muscular disorder with a progressive nature that leads to reduced mobility, physical disability, falls, and poor quality of life. We aimed to evaluate the frequency of objectively diagnosed sarcopenia in patients with ITP and to determine whether ITP therapies have sarcopenic effects.
METHODS: This prospective study included patients who were followed up with ITP in the hematology outpatient clinic. Patients who had received corticosteroids within 3 months were excluded. The handgrip strength test, appendicular skeletal muscle mass (ASMM), ASMM/height2 value, soft lean mass (SLM), trunk soft lean mass (SLMT), and the 6-min walking speed test were applied for muscular evaluations and physical performance assessment.
RESULTS: We included 53 patients (female/male: 73.58%/26.42%). While sarcopenia was not observed in 77.36% of ITP patients, possible sarcopenia was diagnosed in 9.43% and confirmed sarcopenia in 13.21%. Severe sarcopenia was not seen in any of the patients. Loss of muscle strength was observed in 22.64% of patients. SLM was found to be low in 92.45%.
CONCLUSION: Sarcopenia may be more frequent among patients with ITP compared to the population, and it is important to note that 92.45% of patients had low SLM and 54.72% had low SLMT. Eltrombopag therapy might be beneficial as demonstrated by higher SLM, ASMM, and ASMM/height2 values.
The utility model discloses a veterinary medicine tablet convenient to regulate the dosage. The tablet is of a trapezoid shape and mainly consists of an upper surface, a lower surface, an upper lateral surface, a lower lateral surface and indentations. The overall tablet is uniformly divided into two equal parts by the indentation on the upper surface. The overall table is uniformly divided into three equal parts by the indentations on the lower surface. The indentation on the upper surface is vertical to the upper lateral surface and the lower lateral surface of the tablet, starts from the midpoint of the upper lateral surface and stops at the midpoint of the lower lateral surface. The indentations on the lower surface start from the end points at both ends of the upper lateral surface and stop at the midpoint of the lower lateral surface. The indentations are of a V shape. In the process of regulating the dosage, the dosage of the overall tablet can be conveniently regulated into half of the dosage by a knife or scissors or directly by a hand along the indentation on the upper surface; and the dosage of the overall tablet can be conveniently regulated into one third or two thirds of the dosage along the indentations on the lower surface. The veterinary medicine tablet convenient to regulate the dosage is particularly suitable for the requirements on regulating the dosage of different types of animals and fowls and the same type of domestic animals at different ages and has wide application prospect.
This Total Body HIIT program (circuit and bike training) will involve 3 sessions per week (35-40 min on nonconsecutive days) progressed across the 12 weeks. All session will be lead by undergraduate exercise science students or doctor of physical therapy students and supervised by a physical therapist.
Collaboration is a broad concept with different definitions in the literature. Researches on physician-nurse collaboration and nurse-nurse collaboration has shown that improves the quality of patient care; reduces the medical errors; affects the job satisfaction positively and decreases the intention to quit in the international literature. In the light of this information, the study was planned to determine the level of collaboration and the factors affecting its between physicians-nurses and nurses-nurses working in different hospitals. Research is a cross-sectional study. The study is planned the 500 nurses working in six hospitals in Ordu/Turkey on January 3-12 February 2019. Descriptive questionnaire form, Jefferson Scale of Physician-Nurse Collaboration (JSAPNC) and nurse-nurse collaboration scale will be used in the study.
Imaging tools for kidney inflammation could improve care for patients suffering inflammatory kidney diseases by lessening reliance on percutaneous biopsy or biochemical tests alone. During kidney inflammation, infiltration of myeloid immune cells generates a kidney microenvironment that is oxidizing relative to normal kidney. Here, we evaluated whether magnetic resonance imaging (MRI) using the redox-active iron (Fe) complex Fe-PyC3A as an oxidatively activated probe could serve as a marker of kidney inflammation using mouse models of unilateral ischemia-reperfusion injury (IRI) and lupus nephritis (MRL-lpr mice). We imaged unilateral IRI in gp91phox knockout mice, which are deficient in the nicotinamide oxidase II (NOX2) enzyme required for myeloid oxidative burst, as loss of function control, and imaged MRL/MpJ mice as non-kidney involved lupus control. Gadoterate meglumine was used as a non-oxidatively activated control MRI probe. Fe-PyC3A safety was preliminarily examined following a single acute dose. Fe-PyC3A generated significantly greater MRI signal enhancement in the IRI kidney compared to the contralateral kidney in wild-type mice, but the effect was not observed in the NOX2-deficient control. Fe-PyC3A also generated significantly greater kidney enhancement in MRL-lpr mice compared to MRL/MpJ control. Gadoterate meglumine did not differentially enhance the IRI kidney over the contralateral kidney and did not differentially enhance the kidneys of MRL-lpr over MRL/MpJ mice. Fe-PyC3A was well tolerated at the highest dose evaluated, which was a 40-fold greater than required for imaging. Thus, our data indicate that MRI using Fe-PyC3A is specific to an oxidizing kidney environment shaped by activity of myeloid immune cells and support further evaluation of Fe-PyC3A for imaging kidney inflammation.
Excessive body weight is associated with many chronic metabolic diseases and weight loss, so far, remains the gold standard treatment. However, despite tremendous efforts exploring optimal treatments for obesity, many individuals find losing weight and maintaining a healthy body weight difficult. Weight loss is often not sustainable resulting in weight regain and subsequent efforts to lose weight. This cyclic pattern of weight loss and regain is termed "yoyo dieting" and predisposes individuals to obesity and metabolic comorbidities. How yoyo dieting might worsen obesity complications during the weight recurrence phase remains unclear. In particular, there is limited data on the role of the gut microbiome in yoyo dieting. Gut health distress, especially gut inflammation and microbiome perturbation, is strongly associated with metabolic dysfunction and disturbance of energy homeostasis in obesity. In this review, we summarise current evidence of the crosstalk between the gastrointestinal system and energy balance, and the effects of yoyo dieting on gut inflammation and gut microbiota reshaping. Finally, we focus on the potential effects of post-dieting weight loss in improving gut health and identify current knowledge gaps within the field, including gut-derived peptide hormones and their potential suitability as targets to combat weight regain, and how yoyo dieting and associated changes in the microbiome affect the gut barrier and the enteric nervous system, which largely remain to be determined.
PURPOSE: To obtain a skin external agent highly improved in the safety of the α-tocopheryl retinoate therein and capable of adequately presenting its effect, formulated with an α-tocopheryl retinoate and at least one kind of neutral amino acid. CONSTITUTION: This skin external agent contains pref. >=0.001wt.% (esp. 0.01-2.0wt.%) of an α-tocopheryl retinoate and pref. 0.001-10wt.% of at least one kind of neutral amino acid (glycine, alanine, serine, leucine, phenylalanine, proline, and/or hydroxyproline). The α-tocopheryl retinoate is effective for preventing or treating keratosis etc., and preventing or remedying skin aging.
Stage IV breast cancer (distant metastases) remains a non-curable condition; thus, treatment is considered palliative. However, many patients may live for years with their metastatic disease with a reasonably good quality of life. As for locally advanced primary breast cancers in need of primary medical therapy, lack of responsiveness to regular chemotherapy is associated with a poor prognosis, with a high risk of relapse and, subsequent, breast cancer death. TP53 mutations have been shown to predict a poor response to anthracyclines, a group of cytotoxic agents which is extensively used and which is in general efficacious in breast cancer. Notably, dose-intensification with cyclophosphamide has been found to significantly improve the response rate in TP53 mutated primary breast cancers. Our preliminary experience indicates that the use of dose-dense cyclophosphamide monotherapy every 2nd week with G-CSF support is well tolerated. As for patients with metastatic disease for whom the alternative would be to receive continuous chemotherapy at 3-weekly intervals the hypothesis is that cyclophosphamide given at 2-weekly intervals over a limited time period, followed by a "treatment holiday" among responders should be associated with a non-inferior quality of life all-over. As for patients with TP53 mutated locally advanced breast cancers where standard chemotherapy fails, the hypothesis is that cyclophosphamide dose dense treatment may be an effective treatment option downstaging the tumor prior to surgery.
PURPOSE: To provide the method for enhancing the activity of an antibiotic, tylosin, with the fruit or seed of a Schizandra plant having been used as a Chinese medicine prescription, and further to provide the activity-increasing agent therefor. CONSTITUTION: The method for increasing the activity of the tylosin comprises giving the antibiotic, tylosin, together with the fruit and seed of a Schizandra plant or an organic acid to an animal in various administration forms. And the agent for increasing the activity of the tylosin uses the fruit and seed of the Schizandra plant or the organic acid. Even when the antibiotic, tylosin, is used in a small amount, the same antibacterial effect as those of conventional antibiotics can thereby be obtained. Thus, the dosage of the antibiotic, tylosin, can be reduced, and problems caused by the residue of the antibiotic can be decreased. Further, new potencies can be exhibited against resistant bacteria.
Clorazepate dipotassium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

Clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures.

The effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient.

Clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal.
The control arm will have the same conditioning regimen used in ASSIST study. The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. Peripheral blood stem cells (PBSC) will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
PURPOSE:To provide a cosmetic compound with powder of egg shell and giving durable make-up free from oil-floating and powder-floating. CONSTITUTION:The objective cosmetic contains 0.1-90wt% egg shell powder having particle diameter of 0.01-100mu. Chicken's egg is most preferable as the raw material because of the availability of uniform material. It may be subjected to protein-removal process, purification process or sieving process during or after the pulverization process. Egg shell powder exhibits high moisture and oil-absorption and is effective in preventing the float of oil and powder when compounded to a cosmetic. The type of the cosmetic is arbitrary, i.e. solid powder, emulsion, water-oil binary phase system, water-oil-powder ternary phase system, etc., and the cosmetic may be used for various applications.
Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
1452701 Psychotropic compositions containing 2-substituted morpholines IMPERIAL CHEMICAL INDUSTRIES Ltd 9 April 1975 [7 May 1974] 20013/74 Heading A5B [Also in Divisions C2C and C2P] Pharmaceutical compositions having psychotropic activity comprise, as active ingredient, a 2-substituted morpholine of the general formula: wherein A is -CH 2 CH 2 - or -CH=CH- and X is a phenyl group optionally bearing one or two substituents selected from halogen atoms and C 1-6  alkyl, C 1-6  alkoxy and C 6-10  aryloxy groups, the aryloxy groups themselves being optionally substituted by one or two substituents selected from halogen atoms and C 1-4  alkyl groups, or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutically acceptable carrier or diluent and optionally one or more known drugs selected from neuroleptic-sedative agents, e.g. chlorpromazine, prochlorperazine, trifluoperazine and haloperidol; other sedative drugs and tranquillizers, e.g. chlordiazepoxide, phenobarbitone and amylobarbitone; #-adrenergic blocking agents, e.g. propanolol; drugs used in the treatment of Parkinson's disease, e.g. benzhexol; and other antidepressant drugs, e.g. imipramine, desipramine, amitriptyline and nortriptyline; drugs of the amphetamine type; and monoamineoxidase inhibitors, e.g. phenelzine and mebanazine. They may be administered orally or parenterally in the form of tablets, capsules, aqueous or oily solutions or suspensions, emulsions, sterile injectable aqueous or oily solutions or suspensions, or dispersible powders.
Thioredoxin-reductase 2 (Txnrd2) belongs to the thioredoxin-reductase family of selenoproteins and is a key antioxidant enzyme in mammalian cells to regulate redox homeostasis. Here, we reported that Txnrd2 exerted a major influence in brain damage caused by Intracerebral hemorrhage (ICH) by suppressing endoplasmic reticulum (ER) stress oxidative stress and via Trx2/Prx3 pathway. Furthermore, we demonstrated that pharmacological selenium (Se) rescued the brain damage after ICH by enhancing Txnrd2 expression. Primarily, expression and localization of Txnrd2, Trx2 and Prx3 were determined in collagenase IV-induced ICH model. Txnrd2 was then knocked down using siRNA interference in rats which were found to develop more severe encephaledema and neurological deficits. Mechanistically, we observed that loss of Txnrd2 leads to increased lipid peroxidation levels and ER stress protein expression in neurons and astrocytes. Additionally, it was revealed that Se effectively restored the expression of Txnrd2 in brain and inhibited both the activity of ER stress protein activity and the generation of reactive oxygen species (ROS) by promoting Trx2/Prx3 kilter when administrating sodium selenite in lateral ventricle. This study shed light on the effect of Txnrd2 in regulating oxidative stress and ER stress via Trx2/Prx3 pathway upon ICH and its promising potential as an ICH therapeutic target.
To assess homeostatic turnover of monocytes participants in group 4a will receive the 17D yellow fever vaccine and will be asked to drink deuterium (70% enriched 2H2O) labeled water on Days 0 through 7 post-vaccination. Participants will undergo two fine needle aspirate (FNA) procedures to examine the immune response in the lymph nodes.
All patients will receive anesthetic induction and maintenance as per routine using a combination of propofol, opioids, dexamethasone, and 0.6 mg/kg of rocuronium for induction. Patients will also receive lidocaine 1 mg/kg/hour IV infusion, followed by 3-5 mg of morphine equivalents prior to extubation. Patient monitoring will be according to local practice and consist of electrocardiography, blood pressure, heart rate and bispectral index monitoring. Neuromuscular function will be monitored every 20 minutes using a standardized nerve monitor. After induction and intubation, patients in the Deep Neuromuscular Blockade group (experimental group) will receive additional rocuronium to achieve a NMB blockade of TOF of 0 twitch and maintained at this level until reversal.
A system for allowing members or prospective members to simultaneously contact multiple providers to secure an appointment on short notice. The system also enables the provider to view or obtain requests for appointments from members who the provider may not have previously met and/or served. The system further enables a facilitator (304) to monitor the communication exchanges between members and providers and to intervene directly if needed. The system includes a web application, a provider network, facilitator, a database server, a web server, and a database. The web application includes a web site that facilitates interaction between members, providers, the facilitator and the system. The web site also includes a list of common medical terms, phrases, and pharmaceuticals that are cross-referenced in multiple languages. The provider network processes information provided by users of the system and the database stores information processed in the system.